BAM-15
Also known as: BAM15, Mitochondrial protonophore
Mitochondrial Uncoupler | Metabolic Enhancer
Overview
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.
Key benefits
- Increases fat oxidation without affecting food intake
- Reduces body fat mass in research models
- 7-fold more potent than DNP with better safety
- Does not cause dangerous hyperthermia
- No effect on lean body mass
- Improves insulin sensitivity
- Orally bioavailable
- Activates AMPK and PGC-1α pathways
- Synergistic with GLP-1 agonists (semaglutide)
Mechanism of action
BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.
Molecular data
- Type
- Small molecule (not a peptide)
- Half-life
- ~1.7 hours
Sequence
C16H10F2N6O
Indications
What the research community uses this compound for, with self-reported effectiveness.
Metabolic Research
Combination Therapy Research
Other Research Areas
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 25-50 mg | Once or twice daily | — |
| — | ~10 mg/kg | Daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Generally well-tolerated in research
- Possible mild increase in body temperature (less than DNP)
Rare side effects
- Unknown in humans (limited clinical data)
- Theoretical GI disturbance
Contraindications
- Hyperthyroidism or thyroid disorders
- Heart conditions
- Pregnancy or breastfeeding
- Use of other mitochondrial uncouplers (DNP, FCCP)
- Fever or active infection
Monitoring
- Body temperature
- Heart rate
- Energy levels
- No clinical monitoring protocols established yet
References
Primary literature and clinical-trial data informing this entry.